For the year ending 2025-12-31, PEPG had $11,093K increase in cash & cash equivalents over the period. -$81,899K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Research and development expenses | 71,043 |
| General and administrative expenses | 22,569 |
| Operating loss | -93,612 |
| Interest income | 4,017 |
| Other (expense) income, net | -11 |
| Total other income, net | 4,006 |
| Income tax (expense) benefit | 49 |
| Net loss | -89,655 |
| Depreciation | 1,397 |
| Stock-based compensation expense | 10,609 |
| Amortization and interest accretion related to operating lease | 3,748 |
| Amortization of premiums and accretion of discounts on marketable securities, net | 2,212 |
| Impairment of long-lived assets | 701 |
| Prepaids and other current and non-current assets | -1,074 |
| Accounts payable | -935 |
| Accrued expenses and other non-current liabilities | -3,268 |
| Operating lease liabilities, current and non-current | -3,094 |
| Net cash used in operating activities | -81,635 |
| Purchases of property and equipment | 264 |
| Purchases of marketable securities | 93,971 |
| Maturities of marketable securities | 79,000 |
| Net cash used in investing activities | -15,235 |
| Issuance of common stock in public offering, net of underwriters' fees | 108,100 |
| Payment of offering costs | 413 |
| Proceeds from employee equity plans | 292 |
| Net cash provided by financing activities | 107,979 |
| Effect of exchange rate changes on cash | -16 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 11,093 |
| Cash, cash equivalents and restricted cash at beginning of period | 50,969 |
| Cash, cash equivalents and restricted cash at end of period | 62,062 |
PepGen Inc. (PEPG)
PepGen Inc. (PEPG)